MedTrace Logo

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

NCT03326843 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-04-15

Study results available
· View outcomes & findings →

Summary

Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.

Conditions

Interventions

DRUG

Avatrombopag 60 mg

Oral avatrombopag administered once daily for 5 days prior to procedure.

Sponsors & Collaborators

  • Sobi, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2019-02-25
Completion
2019-02-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326843 on ClinicalTrials.gov